Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.

Thorlund K, Wu P, Druyts E, Eapen S, Mills EJ.

Neuropsychiatr Dis Treat. 2014 May 7;10:767-76. doi: 10.2147/NDT.S60061. eCollection 2014.

2.

Rotigotine transdermal system for the treatment of Parkinson's disease.

Pham DQ, Nogid A.

Clin Ther. 2008 May;30(5):813-24. doi: 10.1016/j.clinthera.2008.05.007. Review.

PMID:
18555929
3.
4.

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.

Giladi N, Asgharnejad M, Bauer L, Grieger F, Boroojerdi B.

J Parkinsons Dis. 2016 Apr 2;6(2):401-11. doi: 10.3233/JPD-150758.

5.

Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.

Kim JM, Chung SJ, Kim JW, Jeon BS, Singh P, Thierfelder S, Ikeda J, Bauer L; Asia Pacific Rotigotine Add-on Study Group.

BMC Neurol. 2015 Feb 28;15:17. doi: 10.1186/s12883-015-0267-7.

6.

Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.

Giladi N, Nicholas AP, Asgharnejad M, Dohin E, Woltering F, Bauer L, Poewe W.

J Parkinsons Dis. 2016 Oct 19;6(4):741-749.

7.

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

Kulisevsky J, Pagonabarraga J.

Drug Saf. 2010 Feb 1;33(2):147-61. doi: 10.2165/11319860-000000000-00000. Review.

PMID:
20082541
8.

Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.

Inzelberg R, Schechtman E, Nisipeanu P.

Drugs Aging. 2003;20(11):847-55. Review.

PMID:
12964891
9.

Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.

Linazasoro G; Spanish Dopamine Agonists Study Group.

J Neurol. 2004 Mar;251(3):335-9.

PMID:
15015015
10.

Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study.

Chung SJ, Kim JM, Kim JW, Jeon BS, Singh P, Thierfelder S, Ikeda J, Bauer L; Asia Pacific Rotigotine Switching Study Group.

Expert Opin Pharmacother. 2015 May;16(7):961-70. doi: 10.1517/14656566.2015.1030336. Epub 2015 Apr 6.

PMID:
25846031
11.

Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.

Zhang ZX, Shang HF, Hu X, Chen S, Zhao Z, Du X, Surmann E, Bauer L, Asgharnejad M.

Parkinsonism Relat Disord. 2016 Jul;28:49-55. doi: 10.1016/j.parkreldis.2016.04.022. Epub 2016 Apr 27.

PMID:
27172830
12.

Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.

Mizuno Y, Nomoto M, Hasegawa K, Hattori N, Kondo T, Murata M, Takeuchi M, Takahashi M, Tomida T; Rotigotine Trial Group.

Parkinsonism Relat Disord. 2014 Dec;20(12):1388-93. doi: 10.1016/j.parkreldis.2014.10.005. Epub 2014 Oct 12.

13.

Dopaminergic agonists in Parkinson's disease.

Alonso Cánovas A, Luquin Piudo R, García Ruiz-Espiga P, Burguera JA, Campos Arillo V, Castro A, Linazasoro G, López Del Val J, Vela L, Martínez Castrillo JC.

Neurologia. 2014 May;29(4):230-41. doi: 10.1016/j.nrl.2011.04.012. Epub 2011 Jul 2. Review. English, Spanish.

14.

Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.

Sanford M, Scott LJ.

CNS Drugs. 2011 Aug;25(8):699-719. doi: 10.2165/11206750-000000000-00000. Review.

PMID:
21790211
15.

Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease.

Zhou CQ, Zhang JW, Wang M, Peng GG.

J Clin Neurosci. 2014 Jul;21(7):1094-101. doi: 10.1016/j.jocn.2013.10.041. Epub 2014 Apr 29. Review.

PMID:
24786715
16.

Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.

Dooley M, Markham A.

Drugs Aging. 1998 Jun;12(6):495-514. Review.

PMID:
9638397
18.

Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.

Timmermann L, Asgharnejad M, Boroojerdi B, Dohin E, Woltering F, Elmer LW.

Expert Opin Pharmacother. 2015;16(10):1423-33. doi: 10.1517/14656566.2015.1049597. Epub 2015 May 22.

PMID:
25997442
19.

Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials.

Chen F, Jin L, Nie Z.

J Pharm Pharm Sci. 2017;20(0):285-294. doi: 10.18433/J3Q35D.

PMID:
28810946
20.

Ropinirole: a review of its use in the management of Parkinson's disease.

Matheson AJ, Spencer CM.

Drugs. 2000 Jul;60(1):115-37. Review.

PMID:
10929932

Supplemental Content

Support Center